Generation and Characterization of Tissue-type Plasminogen Activator Transgenic Rats

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2017 Nov 24

PMID 29168147

Citations 3

Authors

Yusuke Ito

Kengo Noguchi

Yoshiyuki Morishima

Kyoji Yamaguchi

Affiliations

Soon will be listed here.

Abstract

To address a species difference in the responsiveness to human recombinant tissue-type plasminogen activator (rt-PA) between rats and humans, tPA transgenic (Tg) rats were generated and characterized. In the rats, transcriptional regulation of tPA was designed under the control of the endogenous tPA promoter. There were no significant differences in hematological parameters between the tPA Tg and non Tg rats. Plasma tPA concentration was significantly increased and serum free PAI-1 was significantly decreased in the tPA Tg rats. Significant overexpression of tPA mRNA in five major organs was also confirmed in the tPA Tg rats. In contrast, the extent of tPA mRNA induction by pathophysiological stimuli (focal cerebral ischemia) was comparable in the two strains. Earlier increase in the plasma D-Dimer level was observed in the tPA Tg rats in a model of thromboembolism compared with the non Tg rats. On the other hand, there was no statistically significant prolongation of bleeding time in a rat model of bleeding between the two strains. rt-PA showed dose-related blood flow restoration in a rat model of thromboembolic stroke in the tPA Tg rats from a dose (1 mg/kg, i.v.) similar to clinical doses for human stroke patients. In conclusion, tPA Tg rats, in which tPA is overexpressed and endogenous fibrinolytic activity is enhanced without hemostatic abnormality, were generated. tPA Tg rats would be beneficial for the pharmacological and the toxicological evaluation of rt-PA and other various fibrinolytic enhancers.

Citing Articles

Human versus Rat PRF on Collagen Membranes: A Pilot Study of Mineralization in Rat Calvaria Defect Model.

Apaza Alccayhuaman K, Heimel P, Tangl S, Lettner S, Kampleitner C, Panahipour L Bioengineering (Basel). 2024; 11(5).

PMID: 38790282 PMC: 11117948. DOI: 10.3390/bioengineering11050414.

Characterization of Enlarged Tongues in Cloned Piglets.

Park M, Ahn J, Lee M, Lee B, Ock S, Byun S Curr Issues Mol Biol. 2023; 45(11):9103-9116.

PMID: 37998748 PMC: 10670481. DOI: 10.3390/cimb45110571.

Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.

Ito Y, Noguchi K, Morishima Y, Yamaguchi K Blood Coagul Fibrinolysis. 2018; 29(3):314-321.

PMID: 29538006 PMC: 5943070. DOI: 10.1097/MBC.0000000000000723.

References

Testa G, Zhang Y, Vintersten K, Benes V, Pijnappel W, Chambers I . Engineering the mouse genome with bacterial artificial chromosomes to create multipurpose alleles. Nat Biotechnol. 2003; 21(4):443-7. DOI: 10.1038/nbt804. View

Carmeliet P, Stassen J, Schoonjans L, Ream B, van den Oord J, de Mol M . Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest. 1993; 92(6):2756-60. PMC: 288474. DOI: 10.1172/JCI116893. View

Arboix A, AliO J . Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. Curr Cardiol Rev. 2011; 6(3):150-61. PMC: 2994107. DOI: 10.2174/157340310791658730. View

Wu H, Shi G, Bender M . Preparation and purification of microplasmin. Proc Natl Acad Sci U S A. 1987; 84(23):8292-5. PMC: 299528. DOI: 10.1073/pnas.84.23.8292. View

Gong S, Zheng C, Doughty M, Losos K, Didkovsky N, Schambra U . A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature. 2003; 425(6961):917-25. DOI: 10.1038/nature02033. View

Longa E, Weinstein P, Carlson S, Cummins R . Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989; 20(1):84-91. DOI: 10.1161/01.str.20.1.84. View

Tomkins A, Hood R, Levi C, Spratt N . Tissue Plasminogen Activator for preclinical stroke research: Neither "rat" nor "human" dose mimics clinical recanalization in a carotid occlusion model. Sci Rep. 2015; 5:16026. PMC: 4629197. DOI: 10.1038/srep16026. View

Overgaard K, Sereghy T, Pedersen H, Boysen G . Dose-response of rt-PA and its combination with aspirin in a rat embolic stroke model. Neuroreport. 1992; 3(10):925-8. DOI: 10.1097/00001756-199210000-00027. View

Lijnen H, Okada K, Matsuo O, Collen D, Dewerchin M . Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood. 1999; 93(7):2274-81. View

10.

Kuiper J, van de Bilt H, Martin U, Van Berkel T . Uptake, internalization and degradation of the novel plasminogen activator reteplase (BM 06.022) in the rat. Thromb Haemost. 1995; 74(6):1501-10. View

11.

Mokin M, Snyder K, Siddiqui A, Levy E, Hopkins L . Recent Endovascular Stroke Trials and Their Impact on Stroke Systems of Care. J Am Coll Cardiol. 2016; 67(22):2645-55. DOI: 10.1016/j.jacc.2015.12.077. View

12.

Wyseure T, Declerck P . Novel or expanding current targets in fibrinolysis. Drug Discov Today. 2014; 19(9):1476-82. DOI: 10.1016/j.drudis.2014.05.025. View

13.

Wang X, Lee S, Arai K, Lee S, Tsuji K, Rebeck G . Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003; 9(10):1313-7. DOI: 10.1038/nm926. View

14.

Thijs V, Peeters A, Vosko M, Aichner F, Schellinger P, Schneider D . Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke. Stroke. 2009; 40(12):3789-95. DOI: 10.1161/STROKEAHA.109.560201. View

15.

Wang Y, Da Cunha V, Vincelette J, Zhao L, Nagashima M, Kawai K . A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost. 2007; 97(1):54-61. View

16.

Sena E, Briscoe C, Howells D, Donnan G, Sandercock P, Macleod M . Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. J Cereb Blood Flow Metab. 2010; 30(12):1905-13. PMC: 3002882. DOI: 10.1038/jcbfm.2010.116. View

17.

Wang Y, Zhao L, Nagashima M, Vincelette J, Sukovich D, Li W . A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - part I: pharmacological characterization. Thromb Haemost. 2007; 97(1):45-53. View

18.

Oikawa K, Watanabe T, Higuchi S . Comparison of drug disposition between wild-type and novel tissue-type plasminogen activator pamiteplase in rats. Drug Metab Dispos. 2000; 28(9):1087-93. View

19.

Wu J, Siddiqui K, Diamond S . Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis. Thromb Haemost. 1994; 72(1):105-12. View

20.

Albers G, von Kummer R, Truelsen T, Jensen J, Ravn G, Gronning B . Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol. 2015; 14(6):575-84. DOI: 10.1016/S1474-4422(15)00047-2. View